Company Filing History:
Years Active: 2007
Title: Vural Ozdemir: Innovator in Genetic Markers and Alzheimer's Treatment
Introduction
Vural Ozdemir is a notable inventor based in Long Beach, California. He has made significant contributions to the field of genetics, particularly in relation to Alzheimer's treatment. His innovative work focuses on the CDK5 genetic markers and their association with cognitive responses to galantamine.
Latest Patents
Vural Ozdemir holds a patent for "CDK5 genetic markers associated with galantamine response." This patent discloses haplotypes in the CDK5 gene that are linked to cognitive responses to galantamine treatment. The patent outlines compositions and methods for detecting and utilizing these CDK5 haplotypes in various clinical applications. These applications include articles of manufacture comprising galantamine or its derivatives, which are approved for treating patients with specific CDK5 haplotypes. Additionally, the patent describes methods and kits for predicting an individual's response to galantamine based on their haplotype profile, as well as treatment methods for Alzheimer's patients tailored to their haplotype profiles.
Career Highlights
Vural Ozdemir is associated with Pgxhealth, LLC, where he continues to advance his research and innovations. His work has the potential to significantly impact the treatment of Alzheimer's disease, providing new avenues for personalized medicine.
Collaborations
He collaborates with esteemed colleagues, including Jeroen Aerssens and Maria Athanasiou, who contribute to his research endeavors and the development of innovative solutions in the field of genetics.
Conclusion
Vural Ozdemir's contributions to the understanding of genetic markers and their implications for Alzheimer's treatment highlight his role as a leading inventor in the field. His patent on CDK5 genetic markers represents a significant advancement in personalized medicine, paving the way for improved treatment strategies for patients.